32/#1068 Trends in the incidence of ovarian germ cell cancers in us Asians and native Chinese

Abstract

Objectives One of the major changes in the revised 2018 FIGO-staging system is the addition of stage IIIC, which includes patients with pelvic and/or para-aortic lymph node metastases. Therefore, we evaluated the prognostic value of positive pelvic and/or para-aortic lymph nodes in patients with cervical cancer. Methods A nationwide retrospective cohort study was performed by identifying all patients diagnosed with stage IB-IVA between 2005-2018 from the Netherlands Cancer Registry. Data was converted to the FIGO 2018 stage based on the TNM-classification. 5-year and overall survival rates (OS) were estimated with the Kaplan-Meier method. Results Of the included 6,082 patients, 1,740 patients, had pelvic and/or para-aortic lymph node metastases. For patients with FIGO 2009 stage IB-IB1-IIA-IIA1 with pelvic and/or para-aortic lymph node metastases 5-year survival is 77% and OS is 70%, without lymph node metastases survival rates are 92% and 87% (p<0.001). For FIGO 2009 stage IB2-IIA2-IIB, with pelvic and/or para-aortic lymph node metastases 5-year survival is 67% and OS is 62%, without lymph node metastases survival rates are 74% and 65% (p=0.009). FIGO 2009 stage IIIA-IIIB and IVA survival rates are not significantly influenced by pelvic and/or para-aortic lymph node metastases (p=0.640, p=0.939). Patients with FIGO 2018 stage IIIC have a 5-year survival of 65% and OS of 59%. Conclusions Patients with FIGO 2009 stage IB-IB1-IIA-IIA1-IB2-IIA2-IIB cervical cancer with positive pelvic and/or paraaortic lymph node metastases have a significant impaired survival compared to patients without metastases. Survival rates of patients with FIGO 2009 stage IIIA-IIIB-IVA are not significant affected by lymph node metastases.